BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Benlysta (Belimumab (GSK1550188)) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Benlysta (Belimumab (GSK1550188))\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06411249-5627@assetmemo.bio
DTSTAMP:20261121T005029Z
DTSTART;VALUE=DATE:20270629
DTEND;VALUE=DATE:20270630
SUMMARY:Benlysta (Belimumab (GSK1550188)): Phase 4 readout est. (NCT0641124
 9)
DESCRIPTION:Benlysta (Belimumab (GSK1550188))\, phase 4\, Systemic Lupus Er
 ythematosus.\nStudy: A Study Describing the Efficacy and Safety of Belimum
 ab Administered in Adult Participants With Early Systemic Lupus Erythemato
 sus (SLE)\nEstimated primary completion: 29 June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/belimumab-gsk1550188#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06411249
URL:https://assetmemo.bio/drug/belimumab-gsk1550188#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07539857-5627@assetmemo.bio
DTSTAMP:20261121T005029Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Benlysta (Belimumab (GSK1550188)): Phase 2 readout est. (NCT0753985
 7)
DESCRIPTION:Benlysta (Belimumab (GSK1550188))\, phase 2.\nStudy: Belimumab 
 to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory
  B-cell HLA-specificity Profiling to Support Delisting for Transplant Acce
 ss in Highly-sensitized\nEstimated primary completion: 1 January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/belimumab-gsk1550188#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0753985
 7
URL:https://assetmemo.bio/drug/belimumab-gsk1550188#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06381453-5627@assetmemo.bio
DTSTAMP:20261121T005029Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Benlysta (Belimumab (GSK1550188)): Phase 2 readout est. (NCT0638145
 3)
DESCRIPTION:Benlysta (Belimumab (GSK1550188))\, phase 2.\nStudy: Belimumab 
 in Autoimmune Hepatitis\nEstimated primary completion: 30 April 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/belimumab-gsk1550188#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06381453
URL:https://assetmemo.bio/drug/belimumab-gsk1550188#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03543839-5627@assetmemo.bio
DTSTAMP:20261121T005029Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Benlysta (Belimumab (GSK1550188)): Phase 4 readout est. (NCT0354383
 9)
DESCRIPTION:Benlysta (Belimumab (GSK1550188))\, phase 4\, Systemic Lupus Er
 ythematosus.\nStudy: Trial of Belimumab in Early Lupus\nEstimated primary 
 completion: September 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/belimumab-gsk1550188#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03543839
URL:https://assetmemo.bio/drug/belimumab-gsk1550188#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
